A new era of pharmacological innovation
In a major win for patients, the FDA has approved two highly anticipated drugs: Cobenfy for schizophrenia and Dupixent for chronic obstructive pulmonary disease (COPD).
Cobenfy, developed by Karuna Therapeutics and later acquired by Bristol-Myers Squibb, is a game-changer as the first antipsychotic that targets cholinergic receptors, moving away from the standard dopamine-focused treatments. This approval comes after clinical trials showed it significantly reduced symptoms in just five weeks, marking a new, revolutionary approach in schizophrenia treatment after decades of stagnation.
On the respiratory front, Dupixent made headlines as the first biologic approved for COPD patients with an eosinophilic phenotype. Unlike typical COPD therapies that rely on inhalers, Dupixent brings new hope for patients who experience severe exacerbations despite existing treatments. Its approval follows successful studies showing improvements in lung function and quality of life.
Both Cobenfy and Dupixent are landmark steps forward in their fields, offering new options for patients who have had few alternatives and marking a new era of pharmacological innovation. — Andrea Corona
